• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 1
  • 1
  • 1
  • Tagged with
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

SERUM INHIBIN LEVELS IN NORMAL MEN AND MEN WITH IDIOPATHIC INFERTILITY

HIBI, HATSUKI, MIYAKE, KOJI, YOKOI, KEISUKE, KATSUNO, SATOSHI, YAMAMOTO, MASANORI 27 May 1995 (has links)
No description available.
2

Efficacy and safety of clomiphene citrate therapy in patients with male idiopathic infertility: A systematic review

Enriquez Gutierrez, Gianfranco Fabricio, Sosaya Muñoz, Fernando Antonio 22 May 2021 (has links)
Introduction: Male idiopathic infertility is a rising problem globally and a significant challenge in clinical practice. Clomiphene citrate emerges as a promising therapy. Our objective is to synthesize available primary evidence about the efficacy and safety of clomiphene citrate treatment for male idiopathic infertility. Materials and Methods: We carried out a Systematic Review. We performed the primary search in PubMed/MEDLINE, Embase, WoS, Medline, Scopus, Cochrane and Trip Database until December 2020 for RCTs evaluating the effect of clomiphene citrate therapy compared to placebo and other therapies on adult males from any age group with idiopathic infertility diagnosis according to WHO 2010 criteria and ICD-10. The outcomes we studied were divided between efficacy: pregnancy and spermogram changes; and security: adverse effects. We evaluated the risk of bias using the Cochrane® Risk of Bias tool. Results: From 1010 registries, we selected 11 RCTs. Sample sizes varied between 23 and 141 participants. Five studies compared clomiphene citrate versus placebo and the remaining six compared clomiphene versus other therapies. The clomiphene doses used in the intervention group were 25mg and 50mg. For the main outcome, pregnancy, nine studies presented results, only one had a positive effect with unclear results (Ghanem et al. RR 3,00; 95% CI; 1,09 –8,25; p<0,05). Seven trials reported a significant increase in sperm concentration, three reported increased motility and one in morphology. However, these changes did not reflect on the increase in pregnancies. Six studies reported adverse effects out of 291 patients that received clomiphene citrate. 12 participants (4.12%) reported adverse effects, including headache and visual symptoms, no serious adverse effects were presented. Conclusion: Due to the variability and heterogeneity of the studies, a qualitative synthesis could not be realized. Nevertheless, evidence suggests pregnancy would not be achieved and so, their use in male idiopathic infertility could not be recommended. Furthermore, better quality randomized controlled trials with a larger sample size are required to measure its effect more validly and reliably. / Introducción: La infertilidad idiopática masculina es un problema creciente a escala global y un desafío importante en la práctica clínica. El citrato de clomifeno se presenta como una terapia prometedora. El objetivo de nuestro estudio fue sintetizar la evidencia primaria disponible respecto a la eficacia y seguridad del tratamiento con citrato de clomifeno en la infertilidad idiopática masculina. Métodos: Llevamos a cabo una revisión sistemática de ensayos clínicos aleatorizados (ECA). Realizamos la búsqueda primaria en PubMed/Medline, Embase, WOS, Medline, Scopus, Cochrane y Trip Database hasta diciembre de 2020 para estudios que evalúan el efecto del tratamiento con citrato de clomifeno en comparación con placebo u otras terapias en pacientes adultos de cualquier grupo etario con diagnóstico de infertilidad idiopática masculina según los criterios de la OMS 2010 y el CIE-10. Los desenlaces que evaluamos fueron de eficacia: embarazo y cambios en el espermograma, y de seguridad: Eventos adversos (EA) totales, EA serios y que conllevan a EA descontinuar la terapia. Evaluamos el riesgo de sesgo mediante la herramienta Cochrane®. Resultados: De un total de 1010 registros, seleccionamos 11 estudios. Los tamaños de muestra variaron entre 23 a 141 pacientes. Cinco estudios comparan clomifeno frente a placebo y los seis restantes clomifeno frente a otras terapias. Las dosis de clomifeno usadas en el grupo intervención fueron de 25mg y 50mg. Para el desenlace principal en nuestra revisión, embarazo, nueve de los once ensayos presentaron resultados. Solo uno de ellos presentó efecto positivo para el embarazo, aunque con resultados imprecisos (Ghanem et al. RR 3,00; IC 95%; 1,09 –8,25; p<0,05). Siete ensayos reportaron aumento significativo de la concentración espermática, tres reportaron aumento en la motilidad y uno en morfología. Sin embargo, estas mejoras laboratoriales no se reflejaron en el aumento del número de embarazos. Por el lado de seguridad, de los seis estudios que reportaron este desenlace, de un total de 291 pacientes que recibieron Clomifeno, 12 personas (4,12%) reportaron EA, de los cuales tres descontinuaron la terapia por cefalea y molestias visuales, no se reportó EA serios. Conclusión: Dada la variabilidad y heterogeneidad de los estudios no se pudo realizar una síntesis cualitativa. No obstante, la evidencia apunta a que no habría efecto en el logro del embarazo, siendo este la finalidad principal de la terapia. Por, ende basados en la evidencia analizada no se podría recomendar su uso en el tratamiento de infertilidad idiopática. Se requieren estudios aleatorizados controlados de mejor calidad y con mayor tamaño de muestra, para medir de manera más válida y confiable su efecto. / Tesis
3

Úloha mutace genu LIF a relativní zastoupení NK buněk, NKT a T lymfocytů ve folikulární tekutině a krvi žen s různou anamnézou neplodnosti / The role of LIF gene mutations and the relative distribution of NK cells, NKT and T lymphocytes in follicular fluid and blood of women with different history of infertility

Křížan, Jiří January 2011 (has links)
Charles University in Prague Faculty of Natural Sciences Summary of Ph.D. thesis The role of LIF gene mutations and the relative distribution of NK cells, NKT and T lymphocytes in follicular fluid and blood of women with different history of infertility Jiří Křížan Prague 2010 1 | P a g e Doctoral degree programs in biomedicine Charles University in Prague and the Academy of Sciences of the Czech Republic Programme: Biomedicine Chairman of the Subject Board: Doc. RNDr. Vladimír Holáň, Dr.Sc. Place of study: Institute of Microbiology, v.v.i., Academy of the Czech Sciences Vídeňská 1083, 142 20 Prague 4 phone: +420 296 442 318 Autor: Mgr. Jiří Křížan Supervisor: RNDr. Petr Šíma, CSc. The dissertation can be found at Dean's Office Faculty of Charles University in Prague 2 | P a g e CONTENTS Contents 2 Summary 3 1. Introduction 5 2. Hypotheses and aims 6 3. Material and methods 7 Material: 7 Methods: 8 4. Results 10 5. Discussion 12 6. Conclusion 15 7. References 16 Bibliography of Autor: 18 1. papers in extenso (thesis background) 18 2. papers in extenso (without regard to thesis) 19 3 | P a g e SUMMARY The aim of the dissertation thesis "The role of LIF gene mutations and the relative distribution of NK cells, NKT, and T lymphocytes in follicular fluid and blood of women with different history of infertility"...

Page generated in 0.0729 seconds